Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by mikeq113on Sep 22, 2020 5:24pm

89 Views

Post# 31601208

RE:RE:RE:RE:RE:RE:Good news coming

I would love to believe that at some point in the near future the analysts will ascribe some heavily (and I emphasize heavily) discounted value to the Phase III trial pre-approval of the actual protocol. With the submittal and FDA/EMA decision likely coming in the next 60-90 days, I unfortunately do not see that happening.

I know we've heard some follow-up from the RBC analyst regarding the announcement that THTX will be submitting the IND for a Phase III in general NASH, not HIV NASH, but I'm sort of surprised we haven't heard much or anything from anyone else, especially Ed Nash.

SPCEO1, you seem to have had some contact with Ed Nash in the past - have you heard anything from him or spoken to him at all about this new development?

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario